Squarepoint’s Celldex Therapeutics CLDX Stock Holding History

Squarepoint’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-40,000	Closed	-$1.08M	–	3036
2022 Q2	$1.08M	Buy	+40,000	New	+$1.16M	0.01%	1555

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's CLDX Position: Q1 2025 in Review

Squarepoint sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 71,176 shares — an estimated $1.8M sold.

Squarepoint first reported a position in CLDX in Q1 2016 and held it in 23 quarters. The position peaked at $6.03M in Q2 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

Squarepoint reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
Squarepoint sold 71,176 Celldex Therapeutics shares in Q1 2025, an estimated $1.8M.
Squarepoint first reported a position in Celldex Therapeutics in Q1 2016 and held it in 23 quarters.
Squarepoint's Celldex Therapeutics position peaked at $6.03M in Q2 2024.
171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.